Tsutomu Akama 氏

Joined Kyowa Hakko Kogyo (currently Kyowa Hakko Kirin) in 1989, Geron Corporation (Menlo Park, CA, USA) in 2001, and Anacor Pharmaceuticals (Palo Alto, CA, USA) in 2003. Engaged in medicinal chemistry research of small molecule drugs. At Anacor, performed boron-based drug discovery, contributed the development of Kerydin (topical onychomycosis agent), and identified Crisaborole that became the active pharmaceutical ingredient of novel topical non-steroidal atopic dermatitis agent, Eucrisa, which resulted in the $5.2B acquisition by Pfizer in 2016. Currently being an owner-chef of a small restaurant “A-POT(株)” in Kanda, Tokyo.
Obtained M.S. from Tohoku Univ. (1989) and Ph.D. from Niigata Univ. (1998)